Imfinzi + Imdelltra Hits OS Endpoint in Phase III ES-SCLC Trial
AZN is trading near its 52-week low of $146.1 (12% above the low).
Summary
Positive Phase III DeLLphi-305 data show Imfinzi plus Imdelltra significantly improved overall survival and progression-free survival in first-line extensive-stage small cell lung cancer, with no new safety signals.
Key Events · Product Development and Regulatory · AZN
-
Phase III OS Endpoint Met
DeLLphi-305 interim analysis showed Imfinzi plus Imdelltra significantly improved overall survival versus Imfinzi alone in 1st-line ES-SCLC maintenance.
-
PFS and ORR Also Improved
Statistically significant and clinically meaningful improvements in progression-free survival and objective response rate were also demonstrated.
-
Safety Profile Consistent
No new safety signals identified; safety and tolerability were consistent with known profiles of the individual treatments.
-
Regulatory Path Forward
Data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
Analysis · AZN · Life Sciences
A statistically significant and highly clinically meaningful overall survival benefit was demonstrated for AstraZeneca's Imfinzi plus Amgen's Imdelltra over Imfinzi alone in first-line extensive-stage small cell lung cancer maintenance. This marks the first time an immunotherapy plus bispecific T-cell engager combination has shown a survival advantage in this setting, reinforcing Imfinzi as the backbone immunotherapy for SCLC. The result addresses a high unmet need where median OS with current standard of care is only about one year, and could reshape the treatment landscape for roughly 195,000 patients treated annually worldwide.
How filings like this one have moved
In the 30 days to Sep 8, 2026, 45.2% of the 628 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $163.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $252.3B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.